The massive interest of pharmaceutical companies in BTK inhibition resulted in several landmark studies in relapsing and progressive MS.3 In the evolutionRMS 1 and 2 trials in people with active relapsing MS, treatment with evobrutinib was compared to treatment with teriflunomide. Here, BTK is linked to myeloid sarcoma.